78706-26-0

Usage

Uses

Used in Pharmaceutical Industry:
5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE is used as a key intermediate in the synthesis of triazolopyrimidine inhibitors. These inhibitors exhibit potent antimalarial activity, making them valuable in the development of new drugs to combat malaria, a disease that affects millions of people worldwide.
In the synthesis process, 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE serves as a building block for the creation of more complex molecules with enhanced biological activity. 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE's structural features, particularly the presence of the chlorine atoms, allow for further chemical modifications and functionalization, enabling the development of more effective antimalarial agents.
The use of 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE in the pharmaceutical industry highlights its potential as a versatile and valuable compound in the ongoing fight against malaria. Its unique properties and reactivity make it an attractive candidate for further research and development, with the ultimate goal of improving global health and reducing the burden of this devastating disease.

Upstream product

• 61-82-5 3-amino-1,2,4-triazole 
• 105-53-3 diethyl malonate 
• 40775-75-5 [1,2,4]triazolo[1,5-a]pyrimidine-5,7-diol 

Downstream Products

• 134791-18-7 5-{N'-[1-Phenyl-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-23-4 5-{N'-[(E)-3-Phenyl-prop-2-en-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-19-8 5-{N'-[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-24-5 N-[1-Phenyl-meth-(E)-ylidene]-N'-(7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-hydrazine 
• 134791-22-3 5-{N'-[1-(2,4-Dichloro-phenyl)-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-21-2 5-{N'-[1-(2-Nitro-phenyl)-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-20-1 5-{N'-[1-(4-Nitro-phenyl)-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-25-6 N-[(E)-3-Phenyl-prop-2-en-(E)-ylidene]-N'-(7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-hydrazine 
• 134791-35-8 C₁₂H₁₂N₆O₃S 
• 134791-28-9 N-[1-(2,4-Dichloro-phenyl)-meth-(E)-ylidene]-N'-(7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-hydrazine 
• 134791-26-7 N-[1-(4-Nitro-phenyl)-meth-(E)-ylidene]-N'-(7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-hydrazine 
• 134791-27-8 N-[1-(2-Nitro-phenyl)-meth-(E)-ylidene]-N'-(7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-hydrazine 
• 134791-36-9 C₁₇H₂₁N₇O₂S 
• 1469868-37-8 4-(5-(2,6-dimethylphenoxy)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)aminobenzonitrile 

Relevant academic research and scientific papers

BCL6-targeting aromatic ring five-membered aromatic heterocyclic micromolecular organic compound and derivative and application thereof

The invention discloses an aromatic ring five-membered aromatic heterocyclic micromolecular organic compound or related analogues or pharmaceutically acceptable salts thereof. The structures of the compound are shown as formulas (I-IX). The invention also

Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches

In our arduous efforts to develop new potent HIV-1 non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs), novel piperidine-linked [1,2,4]triazolo[1,5-a]pyrimidine derivatives were designed, synthesized and evaluated for their antiviral activities

The identification of GPR3 inverse agonist AF64394; The first small molecule inhibitor of GPR3 receptor function

The identification of the novel and selective GPR3 inverse agonist AF64394, the first small molecule inhibitor of GPR3 receptor function, is described. Structure activity relationships and syntheses based around AF64394 are reported.

Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: Discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach

Guided by crystal structures of HIV-1 RT/DAPY complex and molecular modeling studies, a series of novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives were rationally designed via structure-based core refining approach, synthesized through the readily acces

Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

To identify structurally novel CRF1 receptor antagonists, a series of bicyclic core antagonists, pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a] pyrimidines, imidazo[1,2-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines were designed, synthesized and evaluated as CRF1 receptor antagonists. Compounds 2-27 showed binding affinity (IC50 = 4.2-418 nM) and antagonist activity (EC50 = 4.0-889 nM). Compound 5 was found to show oral efficacy in an Elevated Plus Maze test in rats. Further chemical modification of them led us to discovery of the tricyclic core antagonists pyrazolo[1,5-a]pyrrolo[3,2-e] pyrimidines. The discovery process of these compounds is presented, as is the study of the structure-activity relationship.

Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice

Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance.We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF5-Ph and 3,5-Di-F-4- CF 3-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.

AROMATIC COMPOUND

An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is -NH-, -O-, -CH2-, etc., Y is - CH2-,-CO-,-SO2- etc., Z is a single bond, -CO-, -SO2-, -NH-, -O-, -S-, -CONH-,-SO2NH-, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

ALICYCLIC HETEROCYCLIC COMPOUND

An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.